Brisbane, Oct 13, 2016 AEST (ABN Newswire) - Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its latest institutional roadshow presentation and market update that will be delivered to investors over the next two weeks by CEO & Chairman, Dr Mel Bridges and Co-Founder and Chief Scientific Officer, Dr Tracey Mynott.

Presentation highlights include:

- Data on the growing need for a safe and effective alternative to the use of antibiotics in the production of livestock animals and in humans, in line with the United Nations' statement in September 2016 that drug resistance is "the greatest and most urgent global risk"

- The clear path to launch for Detach(TM), Anatara's natural, non-antibiotic therapeutic to prevent gastrointestinal diseases in pigs, following the Company's recent application to register the product for marketing with the Australian Pesticides and Veterinary Medicines Authority

- An overview of the competitive landscape for other therapeutics used to treat gastrointestinal disease in pigs

- A status update on the Company's efforts to move its technology from pigs into humans, along with the commercial rationale for doing so.

To view the presentation, please visit:

About Anatara Lifesciences Ltd

Anatara Lifesciences ASX ANRAnatara Lifesciences (ASX:ANR) is developing therapeutics for gastrointestinal diseases in production animals and humans. Its lead product Detach(TM) is a natural plant based product that will help address global concerns around the overuse of antibiotics in production animals that is contributing to the rise of so-called "super bugs" that make infectious diseases harder to treat. The Anatara team has a strong track record in biological science as well as building and growing international biotech companies.



Investor and Media inquiries:
Dr Mel Bridges
Chairman, Anatara Lifesciences
Phone: +61-413-051-600
Email: mbridges@anataralifesciences.com

Jane Lowe
IR department
Phone: +61-411-117-774
Email: jane.lowe@irdepartment.com.au

Related Companies

Anatara Lifesciences Ltd

ABN Newswire This Page Viewed:  (Last 7 Days: 124) (Last 30 Days: 691) 

Anatara Lifesciences Ltd NEWS: RECENT VISITS (6007)

Social Media